-

SHAREHOLDER ALERT: Robbins LLP Reminds Shareholders that Aterian, Inc. (ATER), Formerly Mohawk Group Holdings, Inc. (MWK), is Being Sued for Misleading Shareholders

SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Aterian, Inc. (NASDAQ:ATER) (formerly known as Mohawk Group Holdings, Inc.) filed a class action complaint against the Company for violations of the Securities Exchange Act of 1934 between December 1, 2020 and May 3, 2021. Aterian purports to be a "technology-enabled consumer products platform that builds, acquires and partners with e-commerce brands."

If you suffered a loss due to Aterian, Inc.'s misconduct, click here.

Aterian, Inc. (ATER) Made Misstatements Regarding its Business Prospects

According to the complaint, on December 1, 2020, the Company announced that it had acquired the assets of "leading e-commerce business brands Mueller, Purstream, Pohl and Schmitt, and Spiralizer." This announcement and subsequent statements by Company executives touted the Company's M&A strategy, and growth and earnings potential. On this news, the Company's share price jumped 18% on December 2, 2020, to close at $8.12. Shares continued to rise, closing at $17.21 per share on December 31, 2020, and reaching nearly $49.00 per share in mid-February, likely due in part to Aterian's February 2, 2021, acquisition of the assets of e-commerce company Healing Solutions, LLC. Again Aterian touted its M&A strategy and the value Healing Solutions would bring to the Company.

However, defendants misled investors by failing to disclose that: (i) the Company's organic growth is plummeting; (ii) the Company's recent, self-lauded acquisitions were overpayments for flawed assets from questionable sources; (iii) the Company's purported artificial intelligence software is a flawed product that lacks customer interest; and (iv) it uses rebate programs and paid for artificial reviews to pump their product offerings.

On May 4, 2021, analyst Culper Research published a report entitled: "Aterian (ATER): Bought from Felons & Fraudsters, Sold to You." The report noted that "the Company has ties to convicted criminals and is promoting what we believe is an overhyped 'AI' narrative and a string of garbage acquisitions to mask the failure of its already ill-conceived core business." The report ripped the Company's acquisitions, stating "[w]e believe that there are serious problems with Aterian's claims to maintain strong organic growth and to drive M&A synergies: to us, neither of these appears to be the case … In our view, this suggests not only that Aterian is unable to growth EBITDA at acquired business, but that its core business is also failing to produce." On this news, Aterian's stock price fell from its May 3, 2021 close of $20.66 to a May 5, 2021 close of $15.72 per share, a two-day drop of approximately 24%.

If you purchased shares of Aterian, Inc. (ATER) between December 1, 2020 and May 3, 2021, you have until July 12, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Aterian, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:ATER

Release Versions
$Cashtags

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Notice: Robbins LLP Informs Investors of the Atara Biotherapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026. Atara develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the United Kingdom (“U.K.”). The Company’s lead product candidate is tabelecleucel (also referred to as tab-cel or EBVALLO), a T-ce...

Stockholder Notice: Robbins LLP Informs Investors of the Coty Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Coty Inc. (NYSE: COTY) common stock between November 5, 2025 and February 4, 2026. Coty together with its subsidiaries, manufactures, markets, distributes, and sells branded beauty products worldwide. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Inves...

Investor Notice: Robbins LLP Informs Investors of the Lufax Holding Ltd. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Lufax Holding Ltd. (NYSE: LU) securities between April 7, 2023 and January 26, 2025. Lufax Holding Ltd engages in the retail credit and enablement business to borrowers and institutions in China. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigat...
Back to Newsroom